Work

KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps7585

Authors: David Lavie, John Timmerman, Ramón Garcia Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel Molin, Muhit Ozcan, Ömür Gökmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex Francisco Herrera

Institutions: Hadassah Medical Center, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Complejo Hospitalario de Salamanca, Samsung Medical Center, Sungkyunkwan University, Seoul National University, Seoul National University Hospital, Sheba Medical Center, Universitair Ziekenhuis Leuven, Cleveland Clinic, Uppsala University, Ankara University, Istanbul Medipol University, Moffitt Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), City Of Hope National Medical Center, City of Hope

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379336260

Cites:

Cited by: 3

Related to: 10